ICPT 3Q19 results: http://ir.interceptpharma.com/news-releases/news-release-details/intercept-pharmaceuticals-reports-third-quarter-2019-financial ICPT raised full-year 2019 Ocaliva sales guidance (for PBC indication only) to $245-250M (from the prior range of $235-245M). CC slides: http://ir.interceptpharma.com/static-files/45a2334a-a7ae-4416-bb79-052be89a326e